BeOne Medicines Ltd. – Sponsored ADR $ONC Position Increased by Slow Capital Inc.

Slow Capital Inc. boosted its position in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 51.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,301 shares of the company’s stock after purchasing an additional 9,280 shares during the period. BeOne Medicines accounts for approximately 1.0% of Slow Capital Inc.’s portfolio, making the stock its 28th biggest position. Slow Capital Inc.’s holdings in BeOne Medicines were worth $8,294,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Signaturefd LLC raised its stake in shares of BeOne Medicines by 10.7% during the 4th quarter. Signaturefd LLC now owns 340 shares of the company’s stock worth $103,000 after purchasing an additional 33 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of BeOne Medicines by 21.8% during the 4th quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock valued at $66,000 after buying an additional 39 shares during the last quarter. CWM LLC grew its stake in shares of BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after buying an additional 39 shares in the last quarter. Sequoia Financial Advisors LLC increased its holdings in BeOne Medicines by 4.1% in the third quarter. Sequoia Financial Advisors LLC now owns 1,281 shares of the company’s stock worth $436,000 after buying an additional 50 shares during the last quarter. Finally, Venturi Wealth Management LLC increased its holdings in BeOne Medicines by 3.7% in the fourth quarter. Venturi Wealth Management LLC now owns 1,602 shares of the company’s stock worth $487,000 after buying an additional 57 shares during the last quarter. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Stock Up 0.2%

ONC opened at $320.70 on Friday. The firm has a market cap of $35.19 billion, a P/E ratio of 127.26 and a beta of 0.53. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.08 and a current ratio of 3.41. The business has a 50 day moving average price of $314.16 and a 200 day moving average price of $324.55. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $218.31 and a twelve month high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.58 EPS for the quarter, missing the consensus estimate of $1.60 by ($1.02). BeOne Medicines had a net margin of 5.37% and a return on equity of 10.70%. The company had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. Research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 EPS for the current year.

Insider Activity

In related news, SVP Chan Henry Lee sold 332 shares of the firm’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $311.59, for a total value of $103,447.88. Following the transaction, the senior vice president directly owned 318,370 shares in the company, valued at approximately $99,200,908.30. This trade represents a 0.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 2,333 shares of company stock worth $785,951. 6.62% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ONC. Truist Financial lifted their target price on shares of BeOne Medicines from $400.00 to $412.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Guggenheim increased their price target on shares of BeOne Medicines from $400.00 to $410.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, January 21st. Royal Bank Of Canada upped their price objective on shares of BeOne Medicines from $417.00 to $425.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Finally, Morgan Stanley reissued an “overweight” rating and set a $405.00 target price on shares of BeOne Medicines in a research report on Thursday, January 8th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, BeOne Medicines presently has a consensus rating of “Moderate Buy” and a consensus target price of $385.08.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.